EN | UA
EN | UA

Help Support

Back

Study evaluates cannabis use and its effect on pain in rheumatologic diseases

Study evaluates cannabis use and its effect on pain in rheumatologic diseases Study evaluates cannabis use and its effect on pain in rheumatologic diseases
Study evaluates cannabis use and its effect on pain in rheumatologic diseases Study evaluates cannabis use and its effect on pain in rheumatologic diseases

A meta-analysis and systematic review was conducted to explore the medical use of cannabis in patients suffering from rheumatic diseases.

See All

Key take away

Despite treatment with analgesics or disease-modifying antirheumatic drugs, patients suffering from rheumatic disorders remain in pain and often turn to non-prescribed pharmacological substitutes such as consumption of cannabis. Consuming cannabis was found to be associated with pain improvement.

Background

A meta-analysis and systematic review was conducted to explore the medical use of cannabis in patients suffering from rheumatic diseases.

Method

The EMBASE, Cochrane library, and PubMed databases were extensively explored to find the relevant articles. The incidence of cannabis intake was estimated by metaproportion. Utilizing the inverse-variance method, the differences between users and non-users of cannabis were expressed as standardized mean differences. The effects of cannabis on pain in patients suffering from rheumatologic diseases were also investigated.

Result

Notable in a sample size of 10, 873 participants, about 2900 subjects were found to consume cannabis [incidence 40.4%], and 15.3% of subjects specified that they were currently taking cannabis. Cannabis usage was found to be raised in the four fibromyalgia studies [68.2%, n=611] compared with seven articles concerning rheumatoid arthritis or lupus [26 %, n= 8168].

Cannabis intake was linked with a decline in pain intensity [visual analog scale pain at baseline 8.2 (2.9) vs 5.6 (3.5)mm over time]. Cannabis users were younger [58.4 ±11.4 vs 63.6 ± 12.1)years], more often smokers [Odds ratio, OR 2.91] or unemployed [OR 2.40], and had elevated pain intensity [5.0 ± 2.4 vs 4.1±2.6 mm] compared to non-users. 

Conclusion

Approximately 20% of patients having rheumatologic diseases actively consume cannabis, with alleviation in pain. The issue of cannabis usage in managing such individuals should be discussed during a medical consultation, specifically with cannabis-based standardized pharmaceutical products.

Source:

Rheumatology

Article:

Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and meta-analysis

Authors:

M Guillouard et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: